Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 16, Issue 5, 2001, Pages 381-390

  Malone, C C ^a   Schiltz, P M ^a   Mackintosh, A D ^a   Beutel, L D ^a   Heinemann, F S ^a   Dillman, R O ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOREACTOR; CANCER IMMUNOTHERAPY; CELL GROWTH; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; KIDNEY CANCER; KIDNEY CARCINOMA; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MELANOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

EID: 0035218425     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497801753354285     Document Type: Article

References (28)

1. The clinical experience with interleukin-2 in cancer therapy
2. What to do with IL-2?
3. Separation, phenotyping and limiting dilution of T lymphocytes infiltrating human solid tumors
4. A new approach to adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
5. Culture of tumor infiltrating lymphocytes in hollow fiber bioreactors
6. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin-2 in human metastatic renal cell carcinoma
7. Growth of tumor derived activated T-cells for the treatment of cancer
8. Expansion of activated lymphocytes obtained from renal cell carcinoma in an automated hollow fiber bioreactor
9. Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience
10. Characterization of tumor infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer
11. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes with recombinant interleukin-2: A pilot study
12. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report
13. Tumor-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer
14. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma; a National Biotherapy Study Group trial
15. Continuous infusion interleukin-2 and tumor-derived activated cell as treatment of advanced solid tumors; a National Biotherapy Study Group
16. Interferon-a primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha; as therapy for metastatic renal cell carcinoma
17. Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and interleukin-2
18. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: A pilot study
19. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes
20. Adoptive immunotherapy with tumor infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: A phase I/II pilot trial
21. Adoptive immunotherapy of advanced solid tumors: An eight year clinical experience
22. Multi-center, randomized, phase III trial of CD8 + tumor-infiltrating lymphocytes in combination with recombinant interleukin-8 in metastatic renal cell carcinoma
23. Establishment of multiple tumor cell lines from a patient with melanoma: A simple method to control fibroblast growth
24. Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy
25. Growth of tumor-derived activated T cells for the treatment of advanced cancer
26. Tumor localization by tumor infiltrating lymphocytes labeled with Indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer
27. Use of anti-CD3 monoclonal antibody in the generation of effector cells from human solid tumors for use in cancer biotherapy
28. In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2